8-K: ALX Oncology Reports Strong 2025 Results, Extends Cash Runway

ALX Oncology announced positive full year 2025 financial results, validated its evorpacept biomarker strategy, and extended its cash runway through the first half of 2028 following a $150 million equity offering.

Summary

• ALX Oncology reported a GAAP net loss of ($101.7) million for the full year 2025, an improvement from ($134.9) million in 2024.
• Cash, cash equivalents, and investments totaled $48.3 million as of December 31, 2025, which, combined with $140.4 million net proceeds from a recent financing, extends the cash runway through the first half of 2028.
• The company's CD47-inhibitor evorpacept showed validated biomarker strategy, with CD47 overexpression being predictive of activity and durable benefit in HER2-positive gastric and breast cancers.
• In the Phase 2 ASPEN-06 gastric cancer trial, CD47-high patients (n=43) treated with evorpacept + TRP achieved a 65.0% objective response rate (ORR) versus 26.1% for TRP alone, with a median duration of response (mDOR) of 25.5 months versus 8.4 months.
• The Phase 2 ASPEN-09-Breast trial for evorpacept in HER2-positive breast cancer is enrolling patients, with an expanded target of up to 120 patients to assess ORR in CD47-overexpressing tumors, with topline data for 80 patients expected mid-2027.
• The novel EGFR-targeted antibody-drug conjugate ALX2004 is progressing in its Phase 1 trial, with no dose-limiting toxicities observed in the first two cohorts, and safety data from the dose-escalation phase anticipated in 2H 2026.
• Barbara Klencke, M.D., has been permanently appointed as Chief Medical Officer.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive due to strong clinical data validating a key biomarker, significant progress across its pipeline, and a successful capital raise that substantially extends its financial runway, de-risking future operations.

Positives

• Full year 2025 GAAP net loss decreased to ($101.7) million from ($134.9) million in 2024, indicating improved financial performance.
• Net proceeds of $140.4 million from a registered equity offering in February 2026 significantly extended the cash runway through the first half of 2028, providing financial stability for key clinical milestones.
• Evorpacept's biomarker strategy was validated, with CD47 overexpression identified as a predictive biomarker for response and durable benefit in HER2-positive gastric and breast cancers, de-risking future development.
• Strong clinical data from the Phase 2 ASPEN-06 gastric cancer trial showed a 65.0% ORR and 25.5 months mDOR in CD47-high patients treated with evorpacept + TRP, significantly outperforming TRP alone.
• The Phase 1b/2 trial of evorpacept with zanidatamab in HER2-positive breast cancer also supported CD47 expression as a predictor of therapeutic response.
• ALX2004's Phase 1 trial is progressing well, with no dose-limiting toxicities observed in the initial two dose cohorts, suggesting a favorable safety profile early on.
• Preclinical data for ALX2004 demonstrated potent anti-tumor activity and a favorable safety profile, including no skin toxicity or interstitial lung disease, at clinically relevant doses.
• The permanent appointment of Barbara Klencke, M.D., as Chief Medical Officer provides stable and experienced leadership for clinical development.

Negatives

• The company continues to operate at a net loss, reporting a GAAP net loss of ($101.7) million for the full year 2025, which is typical for a clinical-stage biotechnology company but still represents a burn rate.

Risks

• Clinical trials for evorpacept and ALX2004 may not achieve desired endpoints or demonstrate sufficient efficacy or safety to warrant further development or regulatory approval.
• The company's ability to obtain additional financing may be limited, impacting its capacity to fund ongoing and future research and development activities.
• The predictive potential of CD47 as a biomarker for evorpacept response may not be consistently replicated across all patient populations or cancer indications.
• Regulatory approvals for product candidates are uncertain and may be delayed or not granted, affecting commercialization timelines.
• Competition from other biotechnology and pharmaceutical companies developing cancer therapies could impact market share and profitability.

Future Outlook

The company anticipates multiple meaningful data sets and milestones for evorpacept and ALX2004 in the coming 12 to 18 months. This includes the full biomarker analysis for the evorpacept/zanidatamab combination in May 2026, safety data from the ALX2004 Phase 1 trial in 2H 2026, and topline data for 80 patients from the ASPEN-09-Breast trial in mid-2027. The recent financing is expected to fund operations through the first half of 2028, supporting these key clinical programs.

Management Comments

• "Through strong execution of our targeted clinical development strategy in 2025, we have positioned ourselves to achieve multiple significant catalysts in the clinical programs for evorpacept and ALX2004, two potentially bestand first-in-class agents, in the coming 12 to 18 months."
• "We are particularly pleased that recent topline biomarker data from the Phase 1b/2 trial evaluating evorpacept with zanidatamab in advanced HER2-positive breast cancer reinforce findings from the ASPEN-06 HER2-positive gastric cancer trial, suggesting that CD47 is a predictive biomarker for evorpacept response."
• "These findings strengthen our confidence in the ongoing Phase 2 ASPEN-09-Breast trial, where we will evaluate patient responses by CD47 level to further define the predictive potential of this biomarker among patients with HER2-positive disease that has progressed following ENHERTU."
• "Additionally, we are pleased with the clinical progress of ALX2004, which has successfully cleared the first two dose cohorts in the ongoing Phase 1 trial."
• "The potential of these two novel therapies, coupled with our substantial progress on their respective clinical programs, contributed to the successful completion of our recent financing. With our newly strengthened balance sheet, we now have the opportunity to deliver more robust and meaningful data readouts in both of our ongoing clinical programs, as reflected in our milestone updates."

Industry Context

StockSavvy.ai notes that the validation of CD47 overexpression as a predictive biomarker for evorpacept response is a significant development in the immuno-oncology space. This precision medicine approach, focusing on patient selection based on biomarker status, aligns with broader industry trends aiming to improve therapeutic efficacy and reduce treatment costs by targeting specific patient populations. The progress of ALX2004, an EGFR-targeted ADC, also positions ALX Oncology in a competitive and rapidly evolving field, where ADCs are gaining prominence as a powerful modality for solid tumors. The company's ability to secure substantial financing in the current market environment underscores investor confidence in its pipeline and strategic direction.

Comparison to Industry Standards

• In the Phase 2 ASPEN-06 gastric cancer trial, evorpacept + TRP achieved a 65.0% ORR and 25.5 months mDOR in CD47-high patients, significantly exceeding the 26.1% ORR and 8.4 months mDOR for TRP alone, demonstrating a substantial improvement over standard-of-care in this specific patient population.
• For previously untreated, indolent B-cell non-Hodgkin lymphoma (iNHL), an investigator-sponsored trial of evorpacept in combination with rituximab and lenalidomide demonstrated a 100% ORR and 92% complete response (CR) rate, which compares favorably to historical control rates around 50% CR, indicating a potentially superior regimen.
• The preclinical safety profile of ALX2004, showing no skin toxicity or interstitial lung disease at clinically relevant doses, is a positive differentiator, as these toxicities can be significant concerns for other EGFR-targeted therapies and ADCs in the industry.

Management Changes

Stakeholder Impact

• Shareholders: The successful equity offering and extended cash runway provide financial stability and reduce dilution risk in the near term, while positive clinical updates offer potential for future value appreciation.
• Patients: Progress in clinical trials for evorpacept and ALX2004 offers hope for new, effective treatment options for various cancers, particularly HER2-positive gastric and breast cancers, and EGFR-expressing solid tumors.
• Employees: The company's strengthened financial position and clear clinical development path provide job security and a stable environment for ongoing research and development efforts.
• Creditors: The extended cash runway improves the company's ability to meet its financial obligations.

Next Steps

• Full biomarker analysis from the Phase 1b/2 evorpacept/zanidatamab breast cancer trial to be presented at ESMO Breast Cancer 2026 Annual Congress on May 7, 2026.
• Safety data from the dose-escalation phase of the ALX2004 Phase 1 trial anticipated in 2H 2026.
• Topline data readout for 80 patients from the Phase 2 ASPEN-09-Breast trial anticipated in mid-2027.
• Continue enrollment in the Sanofi-partnered Phase 1/2 UMBRELLA study for evorpacept in multiple myeloma.
• Continue enrollment in the Phase 1 ALX2004 trial, specifically in the third dose cohort at 4mg/kg.

Key Dates

Recommendation

The filing presents compelling positive developments that warrant a 'buy' recommendation for investors with a suitable risk appetite for clinical-stage biotechnology. The validation of CD47 as a predictive biomarker for evorpacept significantly de-risks its development, allowing for more targeted and potentially successful trials. The strong clinical data from ASPEN-06 and the iNHL IST demonstrate meaningful efficacy. Furthermore, the successful $150 million capital raise provides a robust cash runway through 1H 2028, ensuring funding for critical upcoming milestones for both evorpacept and ALX2004. This financial stability, coupled with promising clinical progress and a clear development strategy, positions ALX Oncology for potential significant value creation.

Keywords

ALX Oncology, ALXO, Evorpacept, ALX2004, CD47 inhibitor, EGFR-targeted ADC, Oncology, Cancer therapy, Clinical trials, Biotechnology, HER2-positive cancer, Gastric cancer, Breast cancer, Financial results, Cash runway, Biomarker